ArticlePloS one2012
Cleavage of phage DNA by the Streptococcus thermophilus CRISPR3-Cas system.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed.
- Defense Systems and Prophage Detection in Streptococcus mutans Strains.Molecular oral microbiology · 2026Article
- CRISPR-anti-CRISPR dynamics: evolutionary, ecological and biotechnological perspectives.Archives of microbiology · 2026Review
- Recent advances in therapeutic gene-editing technologies.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Review
- CRISPR-Cas Systems: A Functional Perspective and Innovations.International journal of molecular sciences · 2025Review
- Innovative molecular intervention and precision therapy for atherosclerosis.Frontiers in cardiovascular medicine · 2025Review
- CRISPR/Cas-Mediated Genome Engineering in Plants: Application and Prospectives.Plants (Basel, Switzerland) · 2024Review
- Precision in Action: The Role of Clustered Regularly Interspaced Short Palindromic Repeats/Cas in Gene Therapies.Vaccines · 2024Review
- My host's enemy is my enemy: plasmids carrying CRISPR-Cas as a defence against phages.Proceedings. Biological sciences · 2024Article
- Precision Genome Editing Techniques in Gene Therapy: Current State and Future Prospects.Current gene therapy · 2024Review
- Genetic Databases and Gene Editing Tools for Enhancing Crop Resistance against Abiotic Stress.Biology · 2023Review
- Shaping the future from the small scale: dry powder inhalation of CRISPR-Cas9 lipid nanoparticles for the treatment of lung diseases.Expert opinion on drug delivery · 2023Review
- CRISPR/Cas9 therapeutics: progress and prospects.Signal transduction and targeted therapy · 2023Review
- Contribution of CRISPRable DNA to human complex traits.Communications biology · 2022Review
- Epidemiological and evolutionary consequences of different types of CRISPR-Cas systems.PLoS computational biology · 2022Article
- A truncated anti-CRISPR protein prevents spacer acquisition but not interference.Nature communications · 2022Article
- FrCas9 is a CRISPR/Cas9 system with high editing efficiency and fidelity.Nature communications · 2022Article
- Distribution, Diversity and Roles of CRISPR-Cas Systems in Human and Animal Pathogenic Streptococci.Frontiers in microbiology · 2022Review
- PAM-repeat associations and spacer selection preferences in single and co-occurring CRISPR-Cas systems.Genome biology · 2021Article
- Harnessing the Potential of CRISPR/Cas in Atherosclerosis: Disease Modeling and Therapeutic Applications.International journal of molecular sciences · 2021Review
- CRISPR/Cas: a Nobel Prize award-winning precise genome editing technology for gene therapy and crop improvement.Journal of Zhejiang University. Science. B · 2021Review
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Streptococcus thermophilus, similar to other Bacteria and Archaea, has developed defense mechanisms to protect cells against invasion by foreign nucleic acids, such as virus infections and plasmid transformations. One defense system recently described in these organisms is the CRISPR-Cas system (Clustered Regularly Interspaced Short Palindromic Repeats loci coupled to CRISPR-associated genes). Two S. thermophilus CRISPR-Cas systems, CRISPR1-Cas and CRISPR3-Cas, have been shown to actively block phage infection. The CRISPR1-Cas system interferes by cleaving foreign dsDNA entering the cell in a length-specific and orientation-dependant manner. Here, we show that the S. thermophilus CRISPR3-Cas system acts by cleaving phage dsDNA genomes at the same specific position inside the targeted protospacer as observed with the CRISPR1-Cas system. Only one cleavage site was observed in all tested strains. Moreover, we observed that the CRISPR1-Cas and CRISPR3-Cas systems are compatible and, when both systems are present within the same cell, provide increased resistance against phage infection by both cleaving the invading dsDNA. We also determined that overall phage resistance efficiency is correlated to the total number of newly acquired spacers in both CRISPR loci.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.